MAPK
Catalog No.
Product Name
Application
Product Information
Citations
-
p38α Inhibitor
p38α inhibitor 3 is a selective p38α inhibitor that impedes myoblast differentiation. By targeting the p38 MAPK pathway, this compound plays a crucial role in modulating cellular responses associated with inflammation and stress. Its applications include studying muscle development and cellular signaling processes in various research contexts. -
p38 MAP Kinase Inhibitor
p38 MAP Kinase-IN-2 is a potent inhibitor of the p38 MAP Kinase pathway, primarily involved in cellular stress responses and inflammation. This compound demonstrates significant inhibitory activity, making it valuable for cancer research and the investigation of various inflammatory diseases. Its mechanism and efficacy provide a useful tool for studying the role of p38 MAP Kinase in cellular processes and therapeutic applications. -
p38 MAPK Inhibitor
RPR-200765A methanesulfonate is a potent inhibitor of p38 MAPK, demonstrating an IC50 of 0.050 μM. This compound selectively targets the p38 MAPK pathway while showing minimal activity against Lck, ERK, ZAP70, and SYK. RPR-200765A methanesulfonate effectively inhibits TNFα production, making it a valuable tool for investigating inflammatory diseases and related cellular processes. -
p38α MAP Kinase Inhibitor
BMS-626531 is a selective inhibitor of p38α MAP kinase, demonstrating potent activity against this important signaling pathway. This compound has been shown to effectively modulate cellular responses associated with inflammation and stress, making it a valuable tool in cancer research. Its ability to inhibit p38α MAP kinase renders it useful for investigating mechanisms of tumor progression and potential therapeutic applications in oncology. -
p38 MAPK Inhibitor
p38-α MAPK-IN-6 is a selective inhibitor of the p38α mitogen-activated protein kinase (MAPK). This compound modulates inflammatory responses by inhibiting the activation of p38 MAPK, a key regulator in cellular stress signaling pathways. It is useful in research applications focused on studying inflammatory diseases, neurodegeneration, and cancer biology. -
p38 MAPK Inhibitor
Macranthoin G is a selective inhibitor of p38 MAPK, a critical signaling pathway involved in stress responses. This compound demonstrates protective effects against cytotoxicity induced by amyloid-beta (Aβ) and hydrogen peroxide in neuronal cells by downregulating p38 MAPK activity. Macranthoin G is a valuable tool for research applications related to neurodegenerative diseases, particularly Alzheimer’s Disease. -
p38 MAPK Inhibitor
p38 MAPK-IN-8 is a potent and selective inhibitor of p38 mitogen-activated protein kinase (p38 MAPK). It exhibits strong oral bioavailability, making it an ideal candidate for in vivo studies. This compound is valuable for investigating inflammatory responses, autoimmune disorders, and various cancer pathways, facilitating a deeper understanding of these complex biological processes. -
p38α MAPK/BChE Inhibitor
ARRY-371797 is a potent and orally bioavailable inhibitor of p38α MAPK and butyrylcholinesterase (BChE), demonstrating IC50 values of 12.0 µM for p38α MAPK and 0.13 µM for BChE, with minimal activity against human acetylcholinesterase (hAChE). This compound shows promise for research applications in Alzheimer’s disease, particularly in the context of neuroinflammation and cholinergic system modulation. -
p38 MAP Kinase Inhibitor
p38 MAPK-IN-7 is a selective inhibitor of p38 MAP kinase, exhibiting an IC50 value of 170 nM. This compound demonstrates potent inhibition of p38 MAPK activity, making it a valuable tool for investigating the role of this kinase in various inflammatory diseases, including rheumatoid arthritis and septic shock. Its oral bioavailability enhances its potential for in vivo studies aimed at understanding the therapeutic implications of p38 MAPK modulation. -
p38α Mitogen-Activated Protein Kinase Inhibitor
R 1487 is a highly selective inhibitor of the p38α mitogen-activated protein kinase. It demonstrates promising biological activity by effectively modulating inflammatory signaling pathways, making it a valuable tool in the study of rheumatoid arthritis and other inflammatory conditions. This compound enables researchers to delve into the mechanisms of p38α inhibition and its potential therapeutic applications in chronic inflammatory diseases. -
p38 Inhibitor
PS-166276 is a potent inhibitor of p38 mitogen-activated protein kinase (MAPK). With an IC50 of 28 nM against p38 kinase, it demonstrates significant inhibitory effects while maintaining lower cytotoxicity. This reagent is valuable for research applications focusing on inflammation, cell signaling, and related therapeutic pathways involving p38 MAPK modulation. -
MEK Inhibitor
PD-254552 is a potent inhibitor of MEK (mitogen-activated protein kinase/extracellular signal-regulated kinase kinase), playing a significant role in disrupting MAPK signaling pathways. This compound has demonstrated significant hepatotoxicity and gastrointestinal toxicity in murine models, providing valuable insights for researchers studying the side effects associated with MEK inhibition. Its properties make it a relevant candidate for investigations into cancer therapies and related pharmacological studies. -
p38α Inhibitor
p38α Inhibitor 4 is a selective allosteric inhibitor targeting the p38α MAPK pathway, demonstrated by an IC50 value of 1.2 μM. This compound exhibits specificity for p38α, showing no activity against p38β, p38γ, and p38δ. p38α Inhibitor 4 is valuable for research exploring inflammatory responses, cell signaling pathways, and related disorders where p38α activity plays a critical role. -
p38 MAPK Inhibitor
Anti-inflammatory agent 7 is a selective p38 MAPK inhibitor that modulates the NF-κB/MAPK signaling pathway to inhibit proinflammatory cytokine production. This reagent demonstrates significant anti-inflammatory activity in LPS-treated RAW 264.7 cells and in in vivo models, making it a valuable tool for studying inflammatory responses and developing therapeutic strategies for related diseases. -
p38 Alpha Kinase Inhibitor
CP-944629 is a potent inhibitor of p38 alpha kinase with an IC50 value of 3.2 μM. This compound effectively modulates the p38 MAPK signaling pathway, making it valuable in the study of chronic inflammatory diseases. Its ability to inhibit p38 alpha kinase may provide insights into therapeutic strategies for conditions driven by excessive inflammation. -
P38 MAPK Inhibitor
NJK14047 is a selective inhibitor of p38 MAPK, a key signaling pathway involved in inflammatory responses. This compound effectively inhibits the differentiation of naive T-cells into Th1 and Th17 cells, thus modulating immune responses. NJK14047 has demonstrated therapeutic potential in preclinical models, ameliorating collagen-induced rheumatoid arthritis and imiquimod-induced psoriasis in mice, making it a valuable tool for research into inflammatory diseases and immune regulation. -
p38 Inhibitor
p38-α MAPK-IN-10 is a potent inhibitor of p38α MAPK, exhibiting an IC50 value of 4 nM. This compound is utilized in research to investigate the role of p38α in inflammatory processes, cellular stress responses, and various pathological conditions. Its selective inhibition makes it an essential tool for studying signal transduction pathways and developing potential therapeutic strategies. -
p38 MAPK Inhibitor Negative Control
SB 202474 is a negative control compound designed for p38 MAPK inhibition studies. Unlike its active analog SB203580, SB 202474 does not inhibit p38 MAPK activity, making it an essential tool for validating experimental results in MAPK pathways. Additionally, it has been shown to suppress melanin synthesis induction, providing further applications in biochemical research related to pigment production. -
p38 Inhibitor
p38 Kinase Inhibitor 7 is a potent inhibitor of p38α with an IC50 value of 5.25 nM. This compound effectively reduces TNFα production in THP-1 cells, demonstrating an IC50 of 5.88 nM. p38 Kinase Inhibitor 7 is valuable for research focused on inflammation and related signaling pathways, making it a useful tool in cytokine modulation studies. -
p38 MAPK Inhibitor
SB-204900 is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK). This compound exhibits significant inhibition of p38 MAPK phosphorylation, making it a valuable tool in the study of inflammatory signaling pathways. SB-204900 is primarily utilized in research focused on understanding the molecular mechanisms underlying inflammatory responses and developing potential therapeutic strategies for related conditions. -
p38α Inhibitor
FS-694 is a potent inhibitor of p38α, exhibiting an IC50 of 0.2 nM. This compound effectively suppresses TNFα release in human whole blood, with an IC50 value of 35.0 nM. FS-694 can be utilized in research aimed at understanding p38α signaling pathways and investigating inflammatory responses. -
p38 MAP Kinase Inhibitor
SC-68376 is a selective, reversible inhibitor of p38 MAP kinase, functioning through competitive inhibition of ATP binding. This compound exhibits significant biological activity in modulating inflammatory responses and cellular stress signaling pathways. SC-68376 is valuable for research applications related to inflammation, neurodegenerative diseases, and cancer, enabling the exploration of p38 MAP kinase's role in various pathological conditions. -
p38-α MAPK Inhibitor
p38-α MAPK-IN-9 is a highly potent inhibitor of the p38-α mitogen-activated protein kinase (MAPK), exhibiting a Ki value of 0.057 nM. This compound effectively inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor-alpha (TNFα) production in human peripheral blood mononuclear cells (hPBMCs), with an IC50 of 18 nM. p38-α MAPK-IN-9 is valuable for research applications focused on inflammatory signaling pathways and the study of cytokine modulation. -
p38 MAPK Inhibitor
p38 MAP Kinase Inhibitor VI is a selective inhibitor of p38 MAPK, exhibiting a moderate inhibition rate of 24%. This compound is instrumental in research focused on inflammation, apoptosis, and cellular stress responses. It can be utilized to explore the role of p38 MAPK in various pathological conditions and to develop therapeutic strategies targeting this signaling pathway. -
p38 Inhibitor
p38 MAP Kinase-IN-1 is a selective inhibitor of the p38 MAP kinase pathway, which plays a crucial role in mediating inflammation and immune responses. This compound is valuable for researchers investigating the mechanisms behind inflammatory diseases and autoimmune disorders. It can facilitate studies aimed at understanding p38's role in cellular signaling and its potential as a therapeutic target in inflammatory-related conditions. -
p38 MAPK Inhibitor
p38 MAPK-IN-6 is a selective p38 MAPK inhibitor that exhibits potential in modulating inflammatory pathways and stress responses. With a demonstrated inhibitory effect of 14% at a concentration of 10 μM, this compound serves as a valuable tool for studying p38 MAPK signaling in various cellular models. Its application extends to research in conditions associated with chronic inflammation and related diseases. -
p38 MAPK Inhibitor
AKP-001 is a selective inhibitor of p38 mitogen-activated protein kinase (p38 MAPK). This compound effectively reduces the production of pro-inflammatory cytokines, making it valuable for studying inflammatory processes. AKP-001 is particularly relevant for research focused on rheumatoid arthritis and inflammatory bowel disease, providing insights into potential therapeutic interventions for these conditions. -
BRD 4/p38α/BRDT Inhibitor
SB-284851-BT is a selective inhibitor of BRD4, p38α, and BRDT. It effectively inhibits BRD4-BD1 with an IC50 of 1.7 µM, p38α with a Kd of 0.47 nM, and exhibits additional inhibitory activity against BRDT and BRD4 with IC50 values of 18 µM and 3.7 µM, respectively. SB-284851-BT significantly reduces IL-8 production through p38α inhibition and downregulates crucial oncogenic pathways such as c-Myc and NF-κB via BRD4 inhibition. This compound has potential applications in cancer research and therapeutic development targeting cellular signaling pathways. -
JNK Inhibitor
JNK-IN-26 is a potent inhibitor of c-Jun N-terminal kinase (JNK), a key signaling enzyme involved in various cellular processes such as apoptosis, inflammation, and stress response. This compound exhibits significant biological activity by selectively inhibiting JNK signaling pathways, making it a valuable tool for studying JNK-related mechanisms in cellular and molecular biology. JNK-IN-26 is utilized in research applications focused on cancer, neurodegenerative diseases, and other conditions involving JNK activation. -
CDK/GSK3β/JNK Inhibitor
Indirubin-3′-oxime (IDR3O) is a synthetic derivative of indirubin that functions as a potent inhibitor of cyclin-dependent kinases (CDKs), glycogen synthase kinase 3β (GSK3β), and all three isoforms of c-Jun N-terminal kinases (JNK1, JNK2, JNK3). It demonstrates inhibitory activity with IC50 values of 0.8 μM, 1.4 μM, and 1.0 μM for each JNK isoform, respectively. Indirubin-3′-oxime is also known to promote chondrocyte height growth through the activation of Wnt/β-catenin signaling, making it relevant for studies in cellular growth and differentiation. -
JNK Inhibitor
J30-8 is a potent and isoform-selective inhibitor of c-Jun N-terminal kinase 3 (JNK3), exhibiting an IC50 value of 40 nM and a remarkable 2500-fold selectivity over JNK1α1 and JNK2α2 isoforms. This compound demonstrates significant neuroprotective activity in vitro, making it a valuable tool for researching neurodegenerative diseases and their therapeutic interventions. -
JNK Activator
CMX-8933 is a JNK activator derived from an octapeptide fragment of the goldfish brain neurotrophic factor ependymin. This compound enhances the enzymatic activity of c-Jun N-terminal kinase (JNK), leading to increased phosphorylation of JNK and c-Jun proteins, as well as elevated cellular levels of c-Jun and c-Fos mRNA. CMX-8933 serves as a valuable tool for investigating the roles of ependymin in neuroplasticity, learning processes, memory formation, and neural regeneration. -
JNK Inhibitor
SR-3306 is a selective pan-JNK (JNK1/2/3) inhibitor with notable brain-penetrating properties. It serves as a neuroprotective agent, making it valuable for investigating neurodegenerative diseases such as Parkinson's disease, as well as conditions related to ischemia/reperfusion (I/R) injury and obesity. Its targeted inhibition of JNK pathways offers potential insights into therapeutic strategies for these disorders. -
JNK3 Inhibitor
JNK3 inhibitor-4 is a selective inhibitor targeting JNK3 (IC50 = 1.0 nM), derived from a 2-aryl-1-pyrimidinyl-1H-imidazole-5-yl acetonitrile scaffold. It demonstrates remarkable selectivity over JNK1 (IC50 = 143.9 nM) and JNK2 (IC50 = 298.2 nM). This compound exhibits neuroprotective properties and shows potential for effective delivery across the blood-brain barrier, making it valuable for research in neurodegenerative diseases and other neurological disorders. -
JNK Inhibitor
JNK3 inhibitor-1 is a potent and selective inhibitor of c-Jun N-terminal kinase 3 (JNK3), exhibiting an IC50 of 0.005 μM. It demonstrates oral bioavailability and the ability to penetrate the blood-brain barrier, making it suitable for neurological research. JNK3 inhibitor-1 is utilized in studies investigating the role of JNK3 in neurodegenerative disorders and various cellular processes. -
JNK1 Inhibitor
JNK-1-IN-3 is a selective inhibitor of JNK1 that effectively downregulates JNK1 gene expression and decreases the levels of its phosphorylated form. This compound concurrently reduces the expression of key downstream targets, including c-Jun and c-Fos, while enhancing p53 activity. JNK-1-IN-3 demonstrates significant antiproliferative effects, especially against renal and breast cancer cell lines, showcasing both in vitro and in vivo anticancer activity, making it a valuable tool for cancer research and therapeutic investigations. -
JNK Inhibitor
JNK-IN-11 is a selective JNK inhibitor, exhibiting IC50 values of 2.2 µM, 21.4 µM, and 1.8 µM for JNK1, JNK2, and JNK3, respectively. This compound demonstrates significant potential in research applications targeting neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease, by modulating pathways involved in cell stress and apoptosis. JNK-IN-11 serves as a valuable tool for investigating therapeutic strategies in these conditions. -
JNK Inhibitor
JNK-IN-13 is a selective inhibitor of the c-Jun N-terminal kinases (JNK), demonstrating IC50 values of 290 nM for JNK3 and 500 nM for JNK2. This compound exhibits significant biological activity in modulating cellular stress responses, apoptosis, and inflammation pathways. JNK-IN-13 is valuable for research applications focused on cancer, neurodegenerative diseases, and metabolic disorders, providing insights into JNK signaling mechanisms. -
JNK Inhibitor
Salicortin is a phenolic glycoside that functions as a JNK inhibitor. It effectively inhibits osteoclast differentiation and bone resorption by down-regulating the JNK and NF-κB/NFATc1 signaling pathways. Salicortin exhibits a range of biological activities, including anti-amnesic, anti-adipogenic, and immune-modulatory effects, making it a valuable tool for research in bone metabolism, neurobiology, and immunology. -
JNK/CYP Inhibitor
JNK-IN-14 is a potent inhibitor of the c-Jun N-terminal kinase (JNK) family, demonstrating IC50 values of 1.81 nM for JNK1, 12.7 nM for JNK2, and 10.5 nM for JNK3. This compound effectively induces early apoptosis and causes cell cycle arrest in the G2/M phase. Additionally, JNK-IN-14 exhibits a modest inhibition of beclin-1 expression in K562 leukemia cells, indicating its potential application in cancer research and therapeutic strategies targeting JNK signaling pathways. -
JNKs Inhibitor
(-)-Zuonin A is a selective inhibitor of c-Jun N-terminal kinases (JNKs), demonstrating IC50 values of 1.7 μM, 2.9 μM, and 1.74 μM for JNK1, JNK2, and JNK3, respectively. As a naturally occurring lignin, it exhibits potent inhibitory activity, making it a valuable reagent for studies investigating JNK signaling pathways. This compound is applicable in research areas including cancer biology, neuroprotection, and inflammation. -
JNK1 Inhibitor
JNK-1-IN-5 is a selective JNK1 inhibitor exhibiting sub-nanomolar activity. This compound effectively suppresses TGF-β-induced epithelial-mesenchymal transition, making it a valuable tool in research focused on pulmonary fibrosis. JNK-1-IN-5 provides a promising avenue for investigating the role of JNK1 in fibrogenic processes and related therapeutic interventions. -
JNK1 Inhibitor
JD123 is a selective inhibitor of JNK1, demonstrating ATP-competitive inhibition of p38-γ MAPK. It effectively reduces the activity of JNK1 and the expression of cJun (1-135), while exhibiting no inhibitory effects on ERK1, ERK2, or the other p38 MAPK isoforms (α, β, and δ). JD123 is primarily utilized in research applications focused on cell signaling pathways, apoptosis, and inflammatory responses. -
JNK Inhibitor
JNK-1-IN-1 is a potent inhibitor of c-Jun N-terminal kinase 1 (JNK-1), demonstrating additional inhibitory effects on MKK7 with an IC50 of 7.8 μM. This compound selectively targets the JNK signaling pathway, which is crucial in regulating various cellular processes such as apoptosis, inflammation, and differentiation. JNK-1-IN-1 is valuable for research applications in cancer biology, neurodegenerative diseases, and inflammatory disorders, providing insights into the modulation of JNK-related signaling pathways. -
JNK-1 Inhibitor
JNK-IN-22 is a selective inhibitor of JNK-1, a key regulator in the stress-activated protein kinase signaling pathway. This compound demonstrates potent inhibition of JNK-1 activity, which is implicated in various cellular processes, including apoptosis, differentiation, and inflammation. JNK-IN-22 is utilized in research to explore its role in neurodegenerative diseases, cancer, and metabolic disorders, making it a valuable tool for understanding JNK-mediated signaling pathways. -
JNK1/2/3 Inhibitor
JNK-IN-25 is a highly selective inhibitor of JNK1, JNK2, and JNK3, exhibiting IC50 values of 1.54 nM, 1.99 nM, and 0.75 nM, respectively. This compound acts by covalently binding to the conserved cysteine residue in the JNK isoforms, thereby obstructing the phosphorylation of c-Jun. JNK-IN-25 is valuable for investigating pathways involved in cancer, as well as in inflammatory and neurodegenerative diseases. -
JNK Inhibitor
CC-401 dihydrochloride is a potent inhibitor of c-Jun N-terminal kinases (JNK) with an inhibition constant (Ki) ranging from 25 to 50 nM. This compound effectively modulates JNK signaling pathways, making it valuable in studies related to cellular stress responses, apoptosis, and inflammatory processes. CC-401 dihydrochloride is applicable in various research areas, including cancer biology and neurodegenerative disease investigations. -
JNK-1 Inhibitor
JNK-IN-21 is a selective inhibitor of JNK-1, a member of the c-Jun N-terminal kinase family, which plays a crucial role in various cellular processes such as apoptosis and inflammation. By blocking JNK-1 activity, JNK-IN-21 demonstrates potential for modulating signaling pathways associated with stress responses and cellular differentiation. This compound is utilized in biological research to investigate JNK-related signaling mechanisms and their implications in disease models. -
JNK2 Inhibitor
JNK2-IN-1 is a selective inhibitor of JNK2, displaying a dissociation constant (Kd) of 79.2 μM. This compound exhibits anti-inflammatory properties by reducing the secretion of pro-inflammatory cytokines TNF-α and IL-6 through the inhibition of the NF-κB/MAPK signaling pathway. JNK2-IN-1 has demonstrated therapeutic potential in alleviating symptoms associated with LPS-induced acute lung injury (ALI) and sepsis, making it valuable for research in inflammation and related diseases. -
JNK Inhibitor
JNK-IN-23 is a potent inhibitor of c-Jun N-terminal kinases (JNK), demonstrating significant antiproliferative activity against MDA-MB-231 cells with a GIC50 of 30 nM. It effectively impedes metastatic growth in triple-negative breast cancer (TNBC) models in vivo, significantly reducing lung metastasis rates. JNK-IN-23 functions through the dual targeting of glutaminase-1 (GLS) and pyruvate dehydrogenase complex (PDHC), making it a valuable tool for research into cancer metabolism and metastasis.
